CLINICAL TRIALS PROFILE FOR LINACLOTIDE
✉ Email this page to a colleague
All Clinical Trials for Linaclotide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00402337 ↗ | Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation | Completed | Ironwood Pharmaceuticals, Inc. | Phase 2 | 2006-11-01 | The primary purpose of this study is to evaluate the efficacy and safety of administration of linaclotide acetate in patients with chronic constipation. |
| NCT00460811 ↗ | Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Completed | Ironwood Pharmaceuticals, Inc. | Phase 2 | 2007-04-01 | The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C. |
| NCT00730015 ↗ | Trial of Linaclotide in Patients With Chronic Constipation | Completed | Forest Laboratories | Phase 3 | 2008-08-01 | The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each dosing group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder. |
| NCT00730015 ↗ | Trial of Linaclotide in Patients With Chronic Constipation | Completed | Ironwood Pharmaceuticals, Inc. | Phase 3 | 2008-08-01 | The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each dosing group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder. |
| NCT00730171 ↗ | An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Completed | Forest Laboratories | Phase 3 | 2008-09-01 | The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C). |
| NCT00730171 ↗ | An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Completed | Ironwood Pharmaceuticals, Inc. | Phase 3 | 2008-09-01 | The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C). |
| NCT00765882 ↗ | Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation | Completed | Ironwood Pharmaceuticals, Inc. | Phase 3 | 2008-09-01 | The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Linaclotide
Condition Name
Clinical Trial Locations for Linaclotide
Trials by Country
Clinical Trial Progress for Linaclotide
Clinical Trial Phase
Clinical Trial Sponsors for Linaclotide
Sponsor Name
